Seres Therapeutics, Inc. (NASDAQ: MCRB)

$7.75 ▼ -0.20 (-2.52%)

As of May 12, 2026 11:48 AM

Sector: Healthcare Industry: Biotechnology CIK: 0001609809

Market Cap 65.56 Mn

P/E 11.21

P/S 83.09

Div. Yield 0.00

Add ratio to table...

About

Seres Therapeutics, Inc. is a clinical-stage company dedicated to improving patient outcomes in medically vulnerable populations through the discovery and development of novel live biotherapeutic product candidates. The company’s core technology centers on live biotherapeutics—defined consortia of bacteria formulated for oral delivery—that aim to modulate host pathways at the mucosal barrier‑immune interface. Its lead product, VOWST, became the first FDA‑approved orally administered microbiome therapeutic and received Breakthrough Therapy...

Seres Therapeutics, Inc. is a clinical-stage company dedicated to improving patient outcomes in medically vulnerable populations through the discovery and development of novel live biotherapeutic product candidates. The company’s core technology centers on live biotherapeutics—defined consortia of bacteria formulated for oral delivery—that aim to modulate host pathways at the mucosal barrier‑immune interface. Its lead product, VOWST, became the first FDA‑approved orally administered microbiome therapeutic and received Breakthrough Therapy designation before being sold to Nestlé Health Science in September 2024. Beyond VOWST, the pipeline includes SER-155, an investigational oral LBP designed to decolonize gastrointestinal pathogens, strengthen epithelial barrier integrity and induce immune homeostasis to prevent bloodstream infections in patients undergoing allogeneic hematopoietic stem cell transplant. SER-603 targets inflammatory bowel disease by restoring microbial balance and promoting mucosal healing without systemic immunosuppression, while SER-147 is being developed to prevent bacterial bloodstream and spontaneous peritonitis infections in patients with chronic liver disease. The firm also advances an oral liquid formulation of SER-155 for intensive care unit patients who cannot swallow capsules, supported by a grant from CARB‑X. Its proprietary discovery engine, the MbTx platform, integrates human clinical data, a curated strain library and artificial‑intelligence driven analytics to identify and optimize bacterial consortia for specific therapeutic effects.

Seres Therapeutics generates revenue principally from the sale of VOWST to Nestlé Health Science, which delivered an upfront payment and potential future milestones tied to the product’s commercial performance. The company also receives research funding and support through strategic partnerships, including a collaboration with the Crohn’s and Colitis Foundation that underpins the development of SER-603 and a multi‑year agreement with Memorial Sloan Kettering Cancer Center for investigator‑sponsored studies of SER-155 in immune‑related enterocolitis. Additionally, SER‑155‑based oral liquid formulation work is financed by a CARB‑X award that provides up to $3.6 million for preclinical activities, manufacturing and a planned Phase 1 trial in ICU patients. While the firm currently has no marketed products besides the divested VOWST, it anticipates future revenue from licensing arrangements, milestone payments and royalties should any of its pipeline candidates achieve regulatory approval. These collaborative and grant‑based inflows supplement its cash resources as it advances clinical programs.

• no_segments_reported.

Seres Therapeutics holds a pioneering stance in the live biotherapeutic arena, having secured the first FDA approval for an orally administered microbiome product and obtained Breakthrough Therapy designations for both VOWST and SER-155. Its integrated platform couples deep human‑derived microbiome data, a functionally characterized strain bank and proprietary machine‑learning tools to design precise bacterial consortia, a capability that differentiates it from many peers focused solely on single‑strain probiotics. The company maintains cGMP manufacturing facilities in Cambridge, Massachusetts, enabling end‑to‑end control from strain selection to final product, a rare advantage among early‑stage biotechs in this modality. Although other companies are pursuing microbiome‑based therapies for indications such as C. difficile infection and inflammatory bowel disease, Seres’ early regulatory milestones, intellectual property portfolio and established clinical trial network give it a competitive edge. Management emphasizes that the combination of scientific know‑how, manufacturing expertise and regulatory experience creates a barrier to entry for newcomers seeking to replicate its approach.

The company’s therapeutic candidates are intended for patients undergoing hematopoietic stem cell transplant, individuals with inflammatory bowel disease, those suffering from chronic liver disease and immunocompromised cancer patients receiving immune‑checkpoint inhibitors. In addition, Seres collaborates with academic medical centers such as Memorial Sloan Kettering Cancer Center and Columbia University, which serve as both research partners and potential future clinical trial sites. Its partnership with the Crohn’s and Colitis Foundation provides access to patient advocacy networks and disease‑specific expertise that inform the development of SER-603. Furthermore, the oral liquid formulation under CARB‑X sponsorship targets intensive care unit patients who are at high risk of antibiotic‑resistant bloodstream infections. Though the firm does not currently sell directly to hospitals or pharmacies, its business model relies on partnerships, licensing and eventual product sales to healthcare providers once candidates receive approval.

Investment thesis

Bull case

The SER‑155 program’s Phase II design aligns closely with FDA expectations and incorporates a pre‑planned interim analysis that is expected to generate meaningful data within twelve months of study initiation. This efficient data‑collection strategy reduces capital burn while keeping the clinical trajectory on track, thereby improving the company’s cost‑efficiency profile and providing an early signal of clinical benefit that could attract strategic partnerships or investors. The company’s ability to secure a $3.6 million non‑dilutive CARB‑X award demonstrates external validation of its platform and provides additional runway to support formulation development for vulnerable patient populations, such as ICU and pediatric cohorts, who lack oral capsule options. These milestones collectively position SER‑155 as a first‑in‑class therapeutic with a differentiated mechanism of action that could significantly reduce bloodstream infection rates in allo‑HSCT patients, potentially transforming standard care and generating substantial value for patients and payers.
The investor‑sponsored study at Memorial Sloan Kettering examining SER‑155 in immune checkpoint‑inhibitor–related enterocolitis offers a unique opportunity to expand the platform beyond infectious indications into high‑unmet inflammatory conditions. Early safety and pharmacology data expected in early 2026 could uncover a new therapeutic niche with an estimated market size in the billions, given the high incidence of enterocolitis among patients receiving checkpoint inhibitors, which currently drive significant hospital costs and treatment interruptions. Successful outcomes could catalyze broader development plans for SER‑155 in ulcerative colitis and Crohn’s disease, tapping into a large, growing patient population that urgently needs non‑immunosuppressive therapies. The expansion into these indications would diversify the company’s revenue streams and mitigate reliance on a single therapeutic area.
Seres’ cost‑reduction initiatives, including a 25 % workforce reduction, have lowered operating expenses and extended the cash runway to 2026 under current plans. By focusing resources on core clinical priorities and securing non‑dilutive funding, the company has improved its financial discipline without compromising the pace of development. The resulting leaner organization is better positioned to negotiate partnership terms and adapt quickly to clinical findings, thereby reducing time‑to‑market and associated capital requirements. This disciplined approach enhances investor confidence and positions the company as a more attractive partner for larger biopharmaceutical firms seeking innovative microbiome solutions.
The Breakthrough Therapy Designation granted by the FDA for SER‑155 in the allo‑HSCT indication provides expedited review pathways and heightened regulatory engagement. This designation not only signals the unmet need and therapeutic promise but also improves the likelihood of favorable reimbursement negotiations once efficacy is proven. The designation may serve as a lever in future funding rounds, enabling the company to command a higher valuation relative to other early‑stage biotechs with similar therapeutic portfolios.
The company’s recent sales figures for Trudanet, with nearly $30 billion in sales last year and an 18 % growth rate, underscore the expanding market for immune checkpoint inhibitors and the associated adverse events such as enterocolitis. SER‑155’s potential to mitigate these adverse events could unlock a significant portion of this growing oncology landscape, creating a new revenue driver that aligns closely with industry trends toward precision and supportive care. By positioning itself as a key solution for a high‑impact safety issue, Seres could capture a meaningful share of oncology supportive‑care spending, further strengthening its commercial outlook.

The SER‑155 program’s Phase II design aligns closely with FDA expectations and incorporates a pre‑planned interim analysis that is expected to generate meaningful data within twelve months of study initiation. This efficient data‑collection strategy reduces capital burn while keeping the clinical trajectory on track, thereby improving the company’s cost‑efficiency profile and providing an early signal of clinical benefit that could attract strategic partnerships or investors. The company’s ability to secure a $3.6 million non‑dilutive CARB‑X award demonstrates external validation of its platform and provides additional runway to support formulation development for vulnerable patient populations, such as ICU and pediatric cohorts, who lack oral capsule options. These milestones collectively position SER‑155 as a first‑in‑class therapeutic with a differentiated mechanism of action that could significantly reduce bloodstream infection rates in allo‑HSCT patients, potentially transforming standard care and generating substantial value for patients and payers.
The investor‑sponsored study at Memorial Sloan Kettering examining SER‑155 in immune checkpoint‑inhibitor–related enterocolitis offers a unique opportunity to expand the platform beyond infectious indications into high‑unmet inflammatory conditions. Early safety and pharmacology data expected in early 2026 could uncover a new therapeutic niche with an estimated market size in the billions, given the high incidence of enterocolitis among patients receiving checkpoint inhibitors, which currently drive significant hospital costs and treatment interruptions. Successful outcomes could catalyze broader development plans for SER‑155 in ulcerative colitis and Crohn’s disease, tapping into a large, growing patient population that urgently needs non‑immunosuppressive therapies. The expansion into these indications would diversify the company’s revenue streams and mitigate reliance on a single therapeutic area.
Seres’ cost‑reduction initiatives, including a 25 % workforce reduction, have lowered operating expenses and extended the cash runway to 2026 under current plans. By focusing resources on core clinical priorities and securing non‑dilutive funding, the company has improved its financial discipline without compromising the pace of development. The resulting leaner organization is better positioned to negotiate partnership terms and adapt quickly to clinical findings, thereby reducing time‑to‑market and associated capital requirements. This disciplined approach enhances investor confidence and positions the company as a more attractive partner for larger biopharmaceutical firms seeking innovative microbiome solutions.
The Breakthrough Therapy Designation granted by the FDA for SER‑155 in the allo‑HSCT indication provides expedited review pathways and heightened regulatory engagement. This designation not only signals the unmet need and therapeutic promise but also improves the likelihood of favorable reimbursement negotiations once efficacy is proven. The designation may serve as a lever in future funding rounds, enabling the company to command a higher valuation relative to other early‑stage biotechs with similar therapeutic portfolios.
The company’s recent sales figures for Trudanet, with nearly $30 billion in sales last year and an 18 % growth rate, underscore the expanding market for immune checkpoint inhibitors and the associated adverse events such as enterocolitis. SER‑155’s potential to mitigate these adverse events could unlock a significant portion of this growing oncology landscape, creating a new revenue driver that aligns closely with industry trends toward precision and supportive care. By positioning itself as a key solution for a high‑impact safety issue, Seres could capture a meaningful share of oncology supportive‑care spending, further strengthening its commercial outlook.

Bear case

Funding remains a critical bottleneck for SER‑155’s Phase II study, as the company has explicitly stated that the study’s commencement is contingent on securing additional capital. The lack of guidance on the exact capital requirement and the absence of any announced partnership or financing round raise significant doubts about the company’s ability to move forward within the projected timeline. This uncertainty could lead to trial delays or even program abandonment, directly impacting potential revenue generation and the company’s valuation.
The 25 % workforce reduction, while extending the cash runway, also signals a constrained resource environment that could hamper the company’s ability to recruit and retain specialized talent essential for advancing complex clinical programs. The reduced personnel levels may limit the capacity to manage multiple concurrent trials, coordinate regulatory submissions, and execute robust data analyses, thereby increasing the risk of operational inefficiencies and trial setbacks.
Although the company reports a positive net income from continuing operations driven by a one‑time gain on the sale of Voust, its ongoing operating loss of $22.5 million in 2024 highlights the volatility of its earnings profile. The reliance on a single, non‑recurring event to achieve profitability makes the company’s financial performance highly unpredictable and exposes it to risk if future non‑recurring gains do not materialize or if the company cannot offset operational expenses through recurring revenue streams.
The investigator‑sponsored study at Memorial Sloan Kettering is small, open‑label, and primarily focused on safety and pharmacology, with no placebo control or statistically powered efficacy endpoint. As a result, even if the study shows early safety signals, it may not provide sufficient evidence to support regulatory approval or attract commercial partners. The limited scope and early stage of this study therefore reduce its potential impact on the company’s growth trajectory.
The CARB‑X grant, while valuable, covers only up to $3.6 million and is aimed at formulation development rather than clinical trial execution. Consequently, the grant does not address the substantial capital required to launch the Phase II study or to sustain the company’s broader development pipeline. Relying on such limited non‑dilutive funding may not be sufficient to offset the ongoing cash burn associated with clinical development and regulatory interactions.

Funding remains a critical bottleneck for SER‑155’s Phase II study, as the company has explicitly stated that the study’s commencement is contingent on securing additional capital. The lack of guidance on the exact capital requirement and the absence of any announced partnership or financing round raise significant doubts about the company’s ability to move forward within the projected timeline. This uncertainty could lead to trial delays or even program abandonment, directly impacting potential revenue generation and the company’s valuation.
The 25 % workforce reduction, while extending the cash runway, also signals a constrained resource environment that could hamper the company’s ability to recruit and retain specialized talent essential for advancing complex clinical programs. The reduced personnel levels may limit the capacity to manage multiple concurrent trials, coordinate regulatory submissions, and execute robust data analyses, thereby increasing the risk of operational inefficiencies and trial setbacks.
Although the company reports a positive net income from continuing operations driven by a one‑time gain on the sale of Voust, its ongoing operating loss of $22.5 million in 2024 highlights the volatility of its earnings profile. The reliance on a single, non‑recurring event to achieve profitability makes the company’s financial performance highly unpredictable and exposes it to risk if future non‑recurring gains do not materialize or if the company cannot offset operational expenses through recurring revenue streams.
The investigator‑sponsored study at Memorial Sloan Kettering is small, open‑label, and primarily focused on safety and pharmacology, with no placebo control or statistically powered efficacy endpoint. As a result, even if the study shows early safety signals, it may not provide sufficient evidence to support regulatory approval or attract commercial partners. The limited scope and early stage of this study therefore reduce its potential impact on the company’s growth trajectory.
The CARB‑X grant, while valuable, covers only up to $3.6 million and is aimed at formulation development rather than clinical trial execution. Consequently, the grant does not address the substantial capital required to launch the Phase II study or to sustain the company’s broader development pipeline. Relying on such limited non‑dilutive funding may not be sufficient to offset the ongoing cash burn associated with clinical development and regulatory interactions.

Consolidation Items Breakdown of Revenue (2025)

Statement of Income Location, Balance Breakdown of Revenue (2025)

Peer comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	109.62 Bn	27.71	9.13	-
2	REGN	Regeneron Pharmaceuticals, Inc.	73.93 Bn	16.38	5.15	1.99 Bn
3	ALNY	Alnylam Pharmaceuticals, Inc.	40.50 Bn	147.21	12.86	-
4	RVMD	Revolution Medicines, Inc.	27.39 Bn	-24.25	33,000.01	-
5	ZLAB	Zai Lab Ltd	23.74 Bn	-135.44	97.90	0.20 Bn
6	MESO	Mesoblast Ltd	23.66 Bn	-185.34	1,375.67	0.12 Bn
7	RPRX	Royalty Pharma plc	21.54 Bn	27.99	9.06	8.95 Bn
8	ROIV	Roivant Sciences Ltd.	19.92 Bn	-32.48	3,470.34	-

Research Tools